Corcept Therapeutics Down Over 48%, on Pace for Largest Percent Decrease Since May 2014 -- Data Talk

Dow Jones01-01

Corcept Therapeutics Incorporated. $(CORT)$ is currently at $36.14, down $34.06 or 48.52%

 

--Would be lowest close since Sept. 12, 2024, when it closed at $35.71

--On pace for largest percent decrease since May 7, 2014, when it fell 50.5%

--Currently down five of the past six days

--Currently down four consecutive days; down 56.77% over this period

--Longest losing streak since Nov. 18, 2025, when it fell for five straight trading days

--Worst four day stretch since the four days ending Aug. 30, 2006, when it fell 64.86%

--Down 54.49% month-to-date; on pace for worst month since Aug. 2006, when it fell 67.65%

--Down 28.29% year-to-date; on pace for worst year since 2012, when it fell 58.19%

--Down 68.36% from its all-time closing high of $114.22 on March 31, 2025

--Down 28.29% from 52 weeks ago (Dec. 31, 2024), when it closed at $50.39

--Down 68.36% from its 52-week closing high of $114.22 on March 31, 2025

--Would be a new 52-week closing low

--Traded as low as $32.99; lowest intraday level since Aug. 5, 2024, when it hit $32.33

--Down 53% at today's intraday low; largest intraday percent decrease since Aug. 25, 2006, when it fell as much as 74.86%

 

All data as of 12:37:24 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 31, 2025 12:40 ET (17:40 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment